Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.59 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9731367 | 0.86 | ALDH1A1 (0.60) | ALDH1A1TAS1R3TAS1R1KMT2AMEN1 | |
| SCHEMBL81121 | 0.82 | MTNR1A (0.57) | ALDH1A1MTNR1AMTNR1BTAS1R3TAS1R1 | |
| SCHEMBL9150411 | 0.77 | ACHE (0.52) | TAS1R3TAS1R1KMT2AMEN1TDP1 | |
| SCHEMBL4464074 | 0.75 | HTR1A (0.78) | — | |
| SCHEMBL21214669 | 0.75 | SMN1; SMN2 (0.45) | ALDH1A1TAS1R3TAS1R1KMT2AMEN1 | |
| SCHEMBL606143 | 0.75 | ALDH1A1 (1.00) | ALDH1A1TAS1R3TAS1R1KMT2AMEN1 | |
| SCHEMBL53323 | 0.75 | ALDH1A1 (1.00) | ALDH1A1TAS1R3TAS1R1KMT2AMEN1 | |
| SCHEMBL55491 | 0.74 | MTNR1A (1.00) | MTNR1AMTNR1B | |
| SCHEMBL4014628 | 0.74 | MTNR1A (0.46) | MTNR1AMTNR1BLMNA | |
| SCHEMBL20478656 | 0.72 | DRD4 (0.50) | MTNR1AMTNR1BTAS1R3TAS1R1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5071875-A | Nervous system, psychological disorders; sleep cycle, skin dis coloration | NORTHWESTERN UNIVERSITY (US) | 1991-12-10 | — | — | US | claimed |
| EP-0420064-A2 | Substituted 2-amidotetralins as melatonin agonists and antagonists | NORTHWESTERN UNIVERSITY (US) | 1991-04-03 | — | — | EP | claimed |
| EP-4706758-A2 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2024-10-03 | — | — | US | disclosed |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-3884935-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-114404588-A | Compounds and methods for inhibiting phosphate transport | 阿德利克斯公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3972599-A1 | COMBINATION FOR LOWERING SERUM PHOSPHATE IN A PATIENT | Ardelyx, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-2120912-B1 | METHODS OF CORRECTING IMBALANCE BETWEEN BONE RESORPTION AND BONE FORMATION AND KITS AND COMPOSITIONS THEREFOR | CHU SAINTE JUSTINE (CA) | 2013-04-03 | — | — | EP | disclosed |
| US-8222298-B2 | Methods of correcting imbalance between bone resorption and bone formation and kits and compositions therefor | CHU SAINTE-JUSTINE (CA) | 2012-07-17 | — | — | US | disclosed |
| US-20100029567-A1 | METHOD OF CORRECTING IMBALANCE BETWEEN BONE RESORPTION AND BONE FORMATION AND KITS AND COMPOSITIONS THEREFOR | CHU SAINTE-JUSTINE (CA) | 2010-02-04 | — | — | US | disclosed |
| EP-2120912-A1 | METHODS OF CORRECTING IMBALANCE BETWEEN BONE RESORPTION AND BONE FORMATION AND KITS AND COMPOSITIONS THEREFOR | Chu Sainte-justine (CA) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008098379-A1 | METHODS OF CORRECTING IMBALANCE BETWEEN BONE RESORPTION AND BONE FORMATION AND KITS AND COMPOSITIONS THEREFOR | CHU SAINTE-JUSTINE (CA) | 2008-08-21 | — | — | WO | disclosed |
| EP-1696959-A2 | MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | Sepracor, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050164987-A1 | Melatonin combination therapy for improving sleep quality | SEPRACOR INC. | 2005-07-28 | — | — | US | disclosed |
| WO-2005063297-A2 | MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | SEPRACOR INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-5151446-A | Neurological disorders or cardiovascular disorders | NORTHWESTERN UNIVERSITY (US) | 1992-09-29 | — | — | US | disclosed |
| US-5071875-A | Nervous system, psychological disorders; sleep cycle, skin dis coloration | NORTHWESTERN UNIVERSITY (US) | 1991-12-10 | — | — | US | disclosed |
| EP-0420064-A2 | Substituted 2-amidotetralins as melatonin agonists and antagonists | NORTHWESTERN UNIVERSITY (US) | 1991-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | ALDH1A1 4094/4885MTNR1A 3262/4885MTNR1B 3128/4885 |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | SLC34A3, SLC34A2, SLC34A1 | ALDH1A1 4094/4885MTNR1A 3262/4885MTNR1B 3128/4885 |
| US-20230277523-A1 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | ALDH1A1 4157/4885MTNR1A 3825/4885MTNR1B 3664/4885 |
| US-20050164987-A1 | Melatonin combination therapy for improving sleep quality | MTNR1A, MTNR1B, CRY1 | ALDH1A1 591/4885MTNR1A 1/4885MTNR1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.